Tetra Bio-Pharma

72 articles with Tetra Bio-Pharma

• Tetra Bio-Pharma Adds Two Board Members and Appoints New COO

  9/17/2020

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP.TO) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that Ms. Dale Weil and Dr. Brent Norton have been appointed to the Company's Board of Directors and Dr. Graham Wood, Ph.D. has been appointed as Chief Operating Officer.

• Tetra Bio-Pharma Appoints Chief Financial Officer

  9/11/2020

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development, is pleased to announce the appointment of Jean-Francois Boily, CPA, CA, as Chief Financial Officer and member of the Company's executive team.

• Dania Scott Joins Tetra Bio-Pharma as Senior Vice President Commercial Strategy

  9/4/2020

  Brings over 20 years of commercial and medical expertise in the pharmaceutical industry and the cannabis space

• Tetra Bio-Pharma Announces Data on its CBD Metabolite Study in Humans

  8/27/2020

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced that it has mapped out CBD metabolites in humans who were administered QIXLEEF™ by vaporization.

• Tetra Bio-Pharma Engages Dalton Pharma for GMP Manufacturing of ARDS-003

  8/18/2020

  Significant advancement achieved with ARDS-003 sterile injectable nano-emulsion finished drug product

• Tetra Bio-Pharma Inc. Virtually Opens The Market

  8/7/2020

  Dr. Guy Chamberland , CEO and Chief Regulatory Officer, Tetra Bio-Pharma Inc. (TSX: TBP), joined his team and Sophie Van Houtte , Head of Company Services, TMX Group, to celebrate the company's graduation from TSX Venture Exchange to Toronto Stock Exchange and open the market. Tetra Bio-Pharma is a biopharmaceutical leader in cannabinoid

• CORRECTION FROM SOURCE: Tetra Bio-Pharma Provides Update on QIXLEEF(TM)'s European Activities

  8/6/2020

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development, is pleased to announce that the Corporation is set to accelerate its European activities.

• Tetra Bio-Pharma Provides Update on QIXLEEF(TM)'s European Activities

  8/6/2020

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development, is pleased to announce that the Corporation is set to accelerate its European activities.

• Tetra Bio-Pharma’s Management Provides Corporate Update on QIXLEEF(TM) & CAUMZ(TM) Drug Development Activities

  7/28/2020

  Resumption of its PLENITUDE© clinical trial on-time; CAUMZ™ manufacturing set to begin in USA to allow start of clinical trials; QIXLEEF™ metabolite mapping study to be complete in Q3 2020

• Tetra Bio-Pharma Provides Management Update on Pharma Focus

  7/27/2020

  Tetra Bio-Pharma Inc. is providing its shareholders with a management update on the Company's Annual General Meeting (AGM) of shareholders commitment to be concentrating 100% of its efforts on its drug development programs with the current focus on ARDS, Plenitude© and Reborn©.

• FDA Provides Positive Feedback on Tetra Bio-Pharma's Pre-Investigational New Drug Application for ARDS-003 to Be Studied in COVID-19 Patients at Risk of Developing Acute Respiratory Distress Syndrome (ARDS)

  7/16/2020

  FDA stated that the nonclinical program was appropriate to support initiating studies in COVID-19 patients

• Tetra Bio-Pharma Appoints Steve Edgett As A Strategic Advisor

  7/9/2020

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has appointed Steve Edgett as a Strategic Advisor. Mr. Edgett will act as a special advisor to the CEO and the Board of Directors with a mandate to advise on strategic and capital markets aspects of the Company's activities and to aid in the advancement of our key programs: ARDS-003, QIXLEEF™ and CAUMZ™.

• Tetra Bio-Pharma Announces Change to its Board of Directors

  6/22/2020

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, today announces the departure of one of its members of the Board of Directors (the "Board).

• Tetra Bio-Pharma and Storz & Bickel Enter into Commercial Sales Agreement for the Mighty Medic Vaporizer

  6/5/2020

  Tetra Bio-Pharma Inc. are pleased to announce that they have finalized a definitive commercial sales agreement for the sale of the Mighty Medic device as part of the CAUMZ™-kit drug-device combination product.

• Tetra Bio-Pharma Provides HCC011 Program Update Following Type B Meeting with USA FDA

  6/4/2020

  HCC011 is an orphan drug designated drug-device combination product for the treatment of hepatocellular carcinoma

• Two Quebec Companies Joined Forces to Make Healthcare Mask for our "Guardian Angels"

  5/18/2020

  Two Quebec Companies Joined Forces to Make Healthcare Mask for our "Guardian Angels"

• 

  Biopharma Update on the Novel Coronavirus: May 5

  5/5/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.

• Tetra Biopharma Confirms Type B Meeting Date With FDA Regarding HCC011FDA Grants Type B meeting to discuss Tetra’s HCC011 with Orphan Drug Designation

  4/6/2020

  Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that the U.S. Food & Drug Administration ("FDA") has granted the Company’s request for a Type B meeting related to its proposed clinical program and overall premarketing requirements for the Company’s product HCC011 with Orphan Drug Designation

• Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following Inhalation of QIXLEEF

  4/2/2020

  Bioanalytical methods developed and validated for its clinical trials. Tetra initiates study to quantify phytocannabinoid metabolites and precursors and minor phytocannabinoids in human plasma. OTTAWA, April 02, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc . (“ Tetra ” or the “ Company ”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the launch of a study to determine the levels of cannabinoid metabolites (e.g., 7-CO

• Tetra Bio-Pharma Announces Filing of Restated Financial Statements and MD&A

  3/30/2020

  Tetra Bio-Pharma Inc. , announced today it has filed an amended and restated management’s discussion and analysis for the financial year ended November 30, 2019 (" Restated MD&A "), which is available on SEDAR under the Corporation's profile. The board of directors of the Corporation, based on the recommendation of the audit committee in consultation with the management of the Corpora